Have any questions? 706-721-6582 or cts@augusta.edu
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS
Clinical Trial
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS
The purpose of this open-label extension study is to offer continued treatment to patients who completed previous studies with rozanolixizumab. This extension will allow us to determine how well patients are able to tolerate this drug when given in 6-week study treatment cycles and whether it improves the condition of their myasthenia gravis. We will monitor patient safety at periodic site visits and documenting any adverse affects.
Eligibility Criteria
- Patient must have: Documented diagnosis of Generalized Myasthenia Gravis Must have participated in the MG0003, MGC003, or MG0004 study through the observational period or needed rescue therapy during the observational period. Patient must not have: severe (defined as Grade 3 on the MG-ADL scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis.
RESEARCH. INNOVATION. DISCOVERY.